Physician profile
Vivek Jain
NPI 1093747248
$2,218.81
in general payments reported to CMS, 2019-2025
16 companies · $76.82 in 2025
The $76.82 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $270 · 2021: $82.32 · 2022: $1,419 · 2023: $38.77 · 2024: $95.86 · 2025: $76.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $211.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $1,350.00 | 2022 | |
| Inspire Medical Systems, INC. | $181.73 | 2020 | |
| Arbor Pharmaceuticals, INC. | $176.76 | 2019-2020 | |
| Allergan, INC. | $79.95 | 2019 | |
| Paratek Pharmaceuticals, INC. | $68.06 | 2021-2024 | Nuzyra |
| Theratechnologies INC. | $56.32 | 2024 | Egrifta, Trogarzo |
| Phathom Pharmaceuticals, INC. | $50.23 | 2025 | Voquezna |
| Dermira, INC. | $44.85 | 2020 | |
| Abbott Laboratories | $39.81 | 2021 | |
| Xeris Pharmaceuticals, INC. | $38.77 | 2023 | Gvoke Hypopen |
| Janssen Products, Lp | $31.49 | 2022 | |
| Harmony Biosciences LLC | $26.59 | 2025 | |
| Amarin Pharma, INC. | $22.44 | 2019 | |
| Biogen, INC. | $19.39 | 2021 | |
| Astellas Pharma US INC | $17.73 | 2024 | Veozah |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $14.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivek Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.